Sign in

    Darin [ph]

    Managing Director and Senior Equity Research Analyst at Jefferies

    Darin Lee is a Managing Director and Senior Equity Research Analyst at Jefferies, specializing in the coverage of the payments, processors, and financial technology sector. He follows leading companies such as Visa, Mastercard, Global Payments, FIS, and Fiserv, with a record of delivering actionable investment insights and earning strong returns for clients. He joined Jefferies in 2019 after holding analyst roles at Compass Point Research & Trading and Morgan Stanley, accumulating more than fifteen years of industry experience. Lee maintains professional credentials including FINRA Series 7, 63, 86, and 87 registrations, and has been recognized in analyst rankings for his accuracy and stock selection performance on platforms such as TipRanks.

    Darin [ph]'s questions to IGM Biosciences (IGMS) leadership

    Darin [ph]'s questions to IGM Biosciences (IGMS) leadership • Q4 2019

    Question

    Darin [ph] from Jefferies asked about expectations for the IGM-2323 data presentation at the 2020 ASH conference, specifically which dose cohorts might be included. He also questioned the manufacturing yield improvements for IGM-2323 and the assumptions underlying the company's stated 12-month clinical supply.

    Answer

    CEO Fred Schwarzer and Chief Medical Officer Dan Chen stated that while the goal is to have dosed the 1,000 mg cohort by ASH, the data presented will depend on enrollment pace and follow-up time. Chief Scientific Officer Bruce Keyt reported that manufacturing yields have approximately doubled since the first run, making them competitive with bispecific IgGs. Keyt and Chen confirmed the 12-month supply calculation is robust, assuming dosing up to 1,000 mg for 10-12 doses, and is sufficient for the Phase 1 trial.

    Ask Fintool Equity Research AI